Cookson Peirce & Co. Inc. raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,460 shares of the medical research company’s stock after acquiring an additional 260 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $3,505,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Bank of Nova Scotia Trust Co. purchased a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $106,000. Keeler Thomas Management LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $106,000. Ropes Wealth Advisors LLC raised its holdings in Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 97 shares during the period. Atlantic Trust LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $138,000. Finally, SeaCrest Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $195,000. 86.54% of the stock is currently owned by institutional investors and hedge funds.
In other news, CFO Stephen Williamson sold 5,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $209.26, for a total transaction of $1,046,300.00. Following the transaction, the chief financial officer now owns 30,741 shares of the company’s stock, valued at approximately $6,432,861.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William G. Parrett sold 1,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $209.80, for a total value of $209,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 95,327 shares of company stock worth $19,470,342 in the last three months. Corporate insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Inc. (NYSE:TMO) opened at $211.71 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $151.74 and a 12-month high of $226.44. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. The stock has a market capitalization of $83,860.17, a price-to-earnings ratio of 37.81, a PEG ratio of 1.53 and a beta of 1.11.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the prior year, the company earned $2.41 EPS. The business’s revenue was up 22.1% compared to the same quarter last year. research analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.71%.
Several analysts recently weighed in on TMO shares. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a report on Tuesday, October 31st. Leerink Swann reiterated an “outperform” rating and issued a $200.00 target price (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Evercore ISI started coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 target price on the stock. Bank of America increased their target price on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Finally, BTIG Research started coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and an average price target of $220.50.
ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/24/cookson-peirce-co-inc-purchases-260-shares-of-thermo-fisher-scientific-inc-tmo.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.